Michael Cher, M.D.
Professor and Chair, Department of Urology
Director of Urologic Oncology - Wayne State University School of Medicine
Chief of Urology - The Barbara Ann Karmanos Cancer Institute
Department of Urology
4201 St. Antoine – 7C UHC
Detroit, MI 48201
Clinical Interests: Minimally Invasive Approaches to Cancer Treatment
I am particularly interested in minimally invasive treatments for prostate cancer and kidney cancer. For prostate cancer, these approaches include robotic-assisted laparoscopic radical prostatectomy, targeted cryoablation of the prostate, focal cryoablation of the prostate, and radioactive seed implantation to the prostate (brachytherapy). For kidney cancer, these approaches include laparoscopic radical nephrectomy and nephroureterectomy, laparoscopic partial nephrectomy, and laparoscopic cryoablation of renal tumors. All of these approaches offer cancer destruction/removal, quick recovery, limited damage to normal tissues, and few side effects.
I also specialize in all other aspects of urologic oncology including cancer of the adrenal gland, kidney cancer, ureteral cancer, bladder cancer, urethral cancer, testis cancer, and penile cancer. My goal is to provide individualized cancer treatments to all patients. In making treatment decisions, it is important to take into account not only the disease stage and tumor grade, but also many other factors such as overall patient health and the particular advantages and disadvantages of various treatment options and procedures. I strive to offer all of the available state-of-the-art treatment options for the various cancers and feel it is critical to involve the patient in the decision-making process.
Multi-Disciplinary Urologic Oncology
Through my work in The Barbara Ann Karmanos Cancer Institute, I also provide patients with the ability to participate in newly developed, multi-disciplinary treatment plans. This team approach often involves several different types of cancer specialists and combinations of different treatments when appropriate. We work very closely with Radiation Oncologists, Medical Oncologists, Pathologists, and Radiologists from the Karmanos Cancer Institute to develop these multi-disciplinary plans.
Special Research Interests
We have a well-funded active basic science research program in the biology of prostate cancer metastasis. Our laboratory is actively involved in determining the biological factors responsible for prostate cancer metastasis to bone marrow because the bone marrow is the most common location for distant spread of prostate cancer. We developed a new experimental model called "SCID-human model of human prostate cancer metastasis to human bone." This animal model has allowed us to investigate many of the biological factors involved in human prostate cancer cells interacting with the human bone microenvironment. In collaboration with other researchers at Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, we have now published over 30 papers in this area of research. Many of our findings have become the basis for clinical trials in patients.
Lucas SM, Kim TK, Ghani KR, Miller DC, Linsell S, Starr J, Peabody JO, Hurley P, Montie J, Cher ML; Michigan Urological Surgery Improvement Collaborative. Establishment of a Web-based System for Collection of Patient-reported Outcomes After Radical Prostatectomy in a Statewide Quality Improvement Collaborative. Urology. 2017 Jun 23. pii: S0090-4295(17)30641-6. [Epub ahead of print]
Auffenberg GB, Lane BR, Linsell S, Cher ML, Miller DC. Practice- vs Physician-Level Variation in Use of Active Surveillance for Men With Low-Risk Prostate Cancer: Implications for Collaborative Quality Improvement. JAMA Surg. 2017 Jun 21. [Epub ahead of print] No abstract available.
Evans R, Loeb A, Kaye KS, Cher ML, Martin ET. Infection-Related Hospital Admissions After Prostate Biopsy in United States Men. Open Forum Infect Dis. 2017;4:ofw265.
Ginsburg KB, Pape K, Heilbronn C, Levin M, Cher ML. Prospective assessment of positioning-related pain in robotic urologic surgery. J Robot Surg. 2017 May 3. [Epub ahead of print]
Telang JM, Lane BR, Cher ML, Miller DC, Dupree JM. Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature. BJU Int. 2017 Mar 29. [Epub ahead of print] Review.
Hawken SR, Auffenberg GB, Miller DC, Lane BR, Cher ML, Abdollah F, Cho H, Ghani KR; Michigan Urological Surgery Improvement Collaborative. Calculating life expectancy to inform prostate cancer screening and treatment decisions. BJU Int. 2017;120:9-11.
Conley-LaComb MK, Semaan L, Singareddy R, Li Y, Heath EI, Kim S, Cher ML, Chinni SR. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. Mol Cancer. 2016;15:68.
Cher ML, Dhir A, Auffenberg GB, Linsell S, Gao Y, Rosenberg B, Jafri SM, Klotz L, Miller DC, Ghani KR, Bernstein SJ, Montie JE, Lane BR; Michigan Urological Surgery Improvement Collaborative. Appropriateness Criteria for Active Surveillance of Prostate Cancer. J Urol. 2017;197(1):67-74.
Cho WJ, Oliveira DS, Najy AJ, Mainetti LE, Aoun HD, Cher ML, Heath E, Kim HR, Bonfil RD. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients. J Transl Med. 2016;14:72.
Tay KJ, Polascik TJ, Elshafei A, Cher ML, Given RW, Mouraviev V, Ross AE, Jones JS. Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. J Endourol. 2016;30:43-8.
Education and Training
BS in Chemistry (1982): Stanford, Palo Alto, California
MD (1986): Washington University School of Medicine, St. Louis, Missouri
Internship/Residency in General Surgery (1986-1988): University of Texas Southwestern Medical Center, Dallas, Texas
Urology Residency (1988-1992): University of Texas Southwestern Medical Center, Dallas, Texas
Urologic Oncology Fellowship (1992-1995): University of California School of Medicine, California